JAK2 and thrombocytosis disease: In addition to thrombocytosis, our Jak2V617F/+ mice did develop erythrocytosis, which persisted in the absence of c-Mpl (Supplementary Table 2); this is likely to depend on activation of the EPO-R by mutant JAK2 as previously suggested [27, 31].